Abstract
In a recent editorial, Pierre Blier discussed some of the reasons that new antidepressants have become a rarity.[1][1] The situation is serious enough that GlaxoSmithKline and Astra-Zeneca have decreased work in many areas of psychiatry, and a recent article in Science asks, “Is pharma running out
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
